Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIn the revolutionary era of biologic drugs, understanding their behavior in vivo is paramount. Creative Biolabs stands at the forefront of this critical field, offering bespoke Anti-idiotype Antibody (Anti-ID Ab) Discovery Services tailored for the robust development of therapeutic antibodies, bispecifics, antibody-drug conjugates (ADCs), and cell therapies. With over two decades of dedicated expertise, we empower our global partners to navigate the complexities of pharmacokinetic (PK), anti-drug antibody (ADA), and neutralizing antibody (NAb) assays with unparalleled precision and reliability. Our services are meticulously designed to support every stage of your drug development pipeline, from preclinical research to post-market surveillance, ensuring your therapeutic candidate meets rigorous regulatory standards.
A therapeutic antibody's antigen-binding site, located in its variable region, contains a unique set of amino acid sequences known as the idiotope (Id). This idiotope is itself immunogenic and can elicit an immune response, leading to the generation of anti-idiotype antibodies (Anti-ID Abs). These specialized antibodies are critical reagents because they specifically recognize the unique idiotope of a particular antibody drug, making them indispensable tools for ligand-binding assays (LBAs) that quantify the drug or detect an immune response against it.
Fig.1 The structure of antibody.
The success of your bioanalytical assays depends entirely on using the correct type of anti-ID antibody. We specialize in discovering and engineering three critical functional classes of anti-IDs:
| Anti-ID Type | Binding Mechanism | Primary Application | Assay Format Examples |
| Type 1: Antigen-Blocking | Binds to the paratope of the drug, directly competing with the target antigen. Mimics the target antigen. | Neutralizing Antibody (NAb) Assays, Free Drug PK Assays | Competitive ELISA, Cell-based Neutralization Assays |
| Type 2: Antigen Non-Blocking | Binds to an idiotope outside the drug's antigen-binding site (paratope). Forms a sandwich with the drug. | Total Drug Pharmacokinetic (PK) Assays, bridging ADA Assays | Bridging ELISA, Sandwich ELISA |
| Type 3: Drug-Target Complex Specific Abs | Binds to a neo-epitope formed only when the drug is bound to its target antigen. | Bound Drug Pharmacokinetic (PK) Assays, Pharmacodynamics (PD) studies | Complex-specific ELISA |
Our strategic approach ensures we design the screening process to isolate the exact functional clone your assay demands, saving you valuable time and resources.
High-quality anti-idiotype antibodies are the cornerstone of modern bioanalysis for therapeutic biologics.
PK assays measure the concentration of a drug in biological matrices over time, defining its absorption, distribution, metabolism, and excretion (ADME) profile.
Regulators worldwide mandate the assessment of immunogenicity—the propensity of a therapeutic biologic to induce an unwanted immune response. Anti-ID antibodies are the gold-standard positive controls and capture/detection reagents for these assays.
A critical subset of ADAs are neutralizing antibodies (NAbs), which can bind to the therapeutic drug and inhibit its biological activity.
| Services | Delivery | Lead time |
| Anti-ID Rabbit Polyclonal Ab Preparation Service |
Purified Ab; Ab QC Report |
3.5 months |
| Anti-ID Mouse Monoclonal Ab Preparation Service | Compete and/or non-compete purified Abs; Ab QC Report; Hybridoma cell line | 5 months |
| Phage Displayed Library Screening of Anti-ID Ab | Purified Ab; Plasmid; Strain; Ab sequences, Ab QC Report | 4 months |
| Development of Immunogenicity Detection Kits | Kit; Manual; R&D report | 3.5 months |
| Development of PK Detection Kits | Kit; Manual; R&D report | 3.5 months |
Creative Biolabs integrates state-of-the-art technologies to guarantee the discovery of high-affinity, high-specificity anti-ID antibodies. We offer a multi-platform approach to de-risk projects and deliver optimal outcomes.
The gold standard for generating robust monoclonal antibodies. Our optimized immunization strategies and proprietary screening methods ensure the development of stable hybridoma cell lines producing high-titer, high-affinity anti-ID antibodies suitable for long-term supply.
Best for: Generating reliable non-blocking (Type 2) and blocking (Type 1) mAbs for PK and ADA assays.
Harness the power of our extensive, custom-built phage display libraries. This in vitro platform allows for rapid selection of binders from vast repertoires, bypassing the limitations of animal immunization. It is exceptionally powerful for discovering antibodies against complex targets or identifying rare, neutralizing clones.
Best for: Rapid discovery of unique binders, including drug-target complex specific (Type 3) antibodies and fully human anti-IDs for reduced immunogenicity in assays.
Isolate rare antibody genes directly from the B-cells of immunized animals. This technology captures the native Vh/Vl pairings, resulting in antibodies with superior affinity and natural pairing. It dramatically accelerates timelines from immunization to recombinant antibody production.
Best for: Ultrafast discovery of high-affinity antibodies; ideal for challenging projects and tight timelines.
A: Typically, we require 1-5 mg of your purified therapeutic antibody drug. If you need anti-IDs against a drug-target complex, we will also need the target antigen.
A: Timelines vary by platform. Single B-cell sorting can deliver recombinant antibodies in as little as 9-12 weeks, while traditional hybridoma development takes approximately 16-20 weeks.
A: Absolutely. We have extensive experience developing anti-ID antibodies for both originator biologics and biosimilars, which is critical for comparative immunogenicity and PK studies.
A: Deliverables are customized but typically include purified polyclonal or monoclonal antibodies (with hybridoma cell lines if applicable), complete characterization data (e.g., affinity, specificity, binning), and a comprehensive final report.
This case study details the development of anti-idiotypic (Anti-ID) antibodies by Creative Biolabs. The project aimed to prepare Fab antigen and generate anti-idiotypic antibodies through mouse immunization and hybridoma screening, ultimately achieving the successful identification and production of desired antibody clones.
DownloadAll listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
